USE OF BIOMARKERS IN EPIDEMIOLOGY - THE EXAMPLE OF METABOLIC SUSCEPTIBILITY TO CANCER

被引:6
作者
VINEIS, P [1 ]
机构
[1] UNIV TURIN,I-10126 TURIN,ITALY
关键词
BIOMARKERS; PHENOTYPE; GENOTYPE; POLYMORPHIC ENZYMES;
D O I
10.1016/0378-4274(95)03286-X
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
This paper examines the methodological problems faced in epidemiological studies which use a particular class of biomarkers, those of genetic susceptibility to cancer. Their use in epidemiology is increasing, they raise special methodological questions and entail particular ethical consequences. A list of questions concerning the validity of the studies is discussed. (1) Is the test used to measure the genotype valid, i.e. sensitive and specific? (2) Is there a discrepancy between the genotype and its phenotypic expression? (3) If so, what conditions are deemed to be responsible for such discrepancy (for example, metabolic impairment due to cancer)? (4) Is there clear evidence that one phenotype is associated with an increased risk of cancer? (5) Is a specific chemical exposure known to be a cause of the cancer at issue and metabolized by the polymorphic enzyme? (6) Can any confounding exposure, i.e. some exposure which is associated with the phenotypic expression (for example by inducing the enzyme activity) and also with cancer risk, be identified? (7) Can any kind of selection bias, i.e. selective inclusion of subjects in the study, conditional to their metabolic status, be identified? (8) Are the results of the studies consistent and internally coherent? For example, does the association appear with all histologic types of cancer at a certain site? If not, is there any convincing explanation for the discrepancies?
引用
收藏
页码:163 / 168
页数:6
相关论文
共 13 条
[1]  
AMOS CI, 1992, CANCER EPIDEM BIOMAR, V1, P505
[2]   RELEVANCE OF METABOLIC POLYMORPHISMS TO HUMAN CARCINOGENESIS - EVALUATION OF EPIDEMIOLOGIC EVIDENCE [J].
CAPORASO, N ;
LANDI, MT ;
VINEIS, P .
PHARMACOGENETICS, 1991, 1 (01) :4-19
[3]  
CHOLERTON S, 1993, BOICH METABOLISM NIC
[4]   A TOBACCO SMOKE-DERIVED NITROSAMINE, 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE, IS ACTIVATED BY MULTIPLE HUMAN CYTOCHROME P450S INCLUDING THE POLYMORPHIC HUMAN CYTOCHROME P4502D6 [J].
CRESPI, CL ;
PENMAN, BW ;
GELBOIN, HV ;
GONZALEZ, FJ .
CARCINOGENESIS, 1991, 12 (07) :1197-1201
[5]   GENETIC ALTERATIONS IN BLADDER-CANCER [J].
DALBAGNI, G ;
PRESTI, J ;
REUTER, V ;
FAIR, WR ;
CORDONCARDO, C .
LANCET, 1993, 342 (8869) :469-471
[6]  
HEIM DW, 1988, BIOCHIM BIOPHYS ACTA, V948, P37
[7]   GENETIC-POLYMORPHISM OF CYTOCHROMES-P450 - INTERETHNIC DIFFERENCES AND RELATIONSHIP TO INCIDENCE OF LUNG-CANCER [J].
INGELMANSUNDBERG, M ;
JOHANSSON, I ;
PERSSON, I ;
YUE, QY ;
DAHL, ML ;
BERTILSSON, L ;
SJOQVIST, F .
PHARMACOGENETICS, 1992, 2 (06) :264-271
[8]  
Kalow W., 1962, PHARMACOGENETICS HER
[9]  
LEMARCHAND L, 1993, NOV P M INT CANC SUS
[10]   CLINICAL-PHARMACOLOGY - POSSIBLE CLINICAL IMPORTANCE OF GENETIC-DIFFERENCES IN DRUG-METABOLISM [J].
NEBERT, DW .
BMJ-BRITISH MEDICAL JOURNAL, 1981, 283 (6290) :537-542